Literature DB >> 35501639

Effects of a New Antithrombotic Drug GRS, a Soluble Guanylate Cyclase Stimulator, on Endothelial Dysfunction in Rats with Myocardial Infarction.

V V Bykov1,2, V I Smol'yakova3, G A Chernysheva3, O I Aliev3, A M Anishchenko4,3, A V Sidekhmenova3, O I Dunaeva3, S A Stankevich5, V A Khazanov5.   

Abstract

New antithrombotic drug GRS, a soluble guanylate cyclase stimulator, after repeated administration in a dose of 10 mg/kg alleviates the symptoms of endothelial dysfunction in rats with myocardial infarction; it restores antiplatelet activity of the blood vessel wall and vasodilatory function of the endothelium without producing significant effect on endothelium-independent vasodilation. GRS also has direct antiaggregant and antihypertensive effects in therapeutic doses. The obtained data suggest that GRS can be therapeutically useful in patients with cardiovascular diseases accompanied by endothelial dysfunction.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  endothelial dysfunction; myocardial infarction; soluble guanylate cyclase stimulator GRS

Mesh：

Substances：

Year:  2022        PMID： 35501639     DOI： 10.1007/s10517-022-05461-y

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN： 0007-4888            Impact factor:   0.804


  8 in total

1.  [The antiaggregation activity of the normal cerebral vessels and in ischemia].

Authors:  N N Petrishchev; S A Shestakova; L N Dorokhova; E V Mel'nikova
Journal:  Fiziol Zh SSSR Im I M Sechenova       Date:  1989-11

Review 2.  Function of cGMP-dependent protein kinases as revealed by gene deletion.

Authors:  F Hofmann; R Feil; T Kleppisch; J Schlossmann
Journal:  Physiol Rev       Date:  2006-01       Impact factor: 37.312

Review 3.  Interaction between platelets and endothelium: from pathophysiology to new therapeutic options.

Authors:  Michalis Hamilos; Stylianos Petousis; Fragiskos Parthenakis
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

4.  Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.

Authors:  Guido Boerrigter; Lisa C Costello-Boerrigter; Alessandro Cataliotti; Harald Lapp; Johannes-Peter Stasch; John C Burnett
Journal:  Hypertension       Date:  2007-02-26       Impact factor: 10.190

5.  Protective role of endothelial progenitor cells stimulated by riociguat in chronic thromboembolic pulmonary hypertension.

Authors:  Keiko Yamamoto; Rintaro Nishimura; Fumiaki Kato; Akira Naito; Rika Suda; Ayumi Sekine; Takayuki Jujo; Ayako Shigeta; Seiichiro Sakao; Nobuhiro Tanabe; Koichiro Tatsumi
Journal:  Int J Cardiol       Date:  2019-07-15       Impact factor: 4.164

Review 6.  Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?

Authors:  Yuliy Y Chirkov; John D Horowitz
Journal:  Pharmacol Ther       Date:  2007-07-24       Impact factor: 12.310

Review 7.  Effects of the NO/soluble guanylate cyclase/cGMP system on the functions of human platelets.

Authors:  Stephanie Makhoul; Elena Walter; Oliver Pagel; Ulrich Walter; Albert Sickmann; Stepan Gambaryan; Albert Smolenski; René P Zahedi; Kerstin Jurk
Journal:  Nitric Oxide       Date:  2018-03-14       Impact factor: 4.427

8.  Soluble Guanylate Cyclase Stimulators and Activators.

Authors:  Peter Sandner; Daniel P Zimmer; G Todd Milne; Markus Follmann; Adrian Hobbs; Johannes-Peter Stasch
Journal:  Handb Exp Pharmacol       Date:  2021
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.